Anti-oestrogen therapy of advanced mammary carcinoma.

H Westerberg, B Nordenskjöld, A de Schryver, G Notter
{"title":"Anti-oestrogen therapy of advanced mammary carcinoma.","authors":"H Westerberg,&nbsp;B Nordenskjöld,&nbsp;A de Schryver,&nbsp;G Notter","doi":"10.3109/02841867609131975","DOIUrl":null,"url":null,"abstract":"<p><p>Forty mg daily of tamoxifen (Nolvadex) was administered orally to 89 patients with advanced soft tissue mammary carcinoma. At two months 43 per cent of the patients responded. At 6, 12 and 18 months, 42, 35 and 32 per cent, respectively, were still responding to therapy. The side effects were limited, fatique being the most frequent complaint. Oestrogen dependent side effects were not encountered. The therapeutic effect of tamoxifen is similar to that of oestrogen, but the side effects are less.</p>","PeriodicalId":7139,"journal":{"name":"Acta radiologica: therapy, physics, biology","volume":"15 6","pages":"513-8"},"PeriodicalIF":0.0000,"publicationDate":"1976-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/02841867609131975","citationCount":"21","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta radiologica: therapy, physics, biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3109/02841867609131975","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 21

Abstract

Forty mg daily of tamoxifen (Nolvadex) was administered orally to 89 patients with advanced soft tissue mammary carcinoma. At two months 43 per cent of the patients responded. At 6, 12 and 18 months, 42, 35 and 32 per cent, respectively, were still responding to therapy. The side effects were limited, fatique being the most frequent complaint. Oestrogen dependent side effects were not encountered. The therapeutic effect of tamoxifen is similar to that of oestrogen, but the side effects are less.

晚期乳腺癌的抗雌激素治疗。
89例晚期软组织乳腺癌患者口服他莫昔芬(Nolvadex),每日40毫克。两个月后,43%的患者有了反应。在6个月、12个月和18个月时,分别有42%、35%和32%的患者仍对治疗有反应。副作用是有限的,疲劳是最常见的抱怨。没有遇到雌激素依赖的副作用。他莫昔芬的治疗效果与雌激素相似,但副作用更小。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信